...
首页> 外文期刊>Archives of gynecology and obstetrics. >Increment in beta-hCG in the 48-h period prior to treatment: a new variable predictive of therapeutic success in the treatment of ectopic pregnancy with methotrexate.
【24h】

Increment in beta-hCG in the 48-h period prior to treatment: a new variable predictive of therapeutic success in the treatment of ectopic pregnancy with methotrexate.

机译:治疗前48小时内β-hCG的增加:预测甲氨蝶呤治疗异位妊娠治疗成功的新变量。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: To evaluate the increment in beta-hCG levels (%) in the 48-h interval prior to treatment as a predictor of therapeutic success in the management of ectopic pregnancy with methotrexate. METHODS: A prospective observational study was carried out between April 2002 and November 2006 at the Federal University of Sao Paulo in 65 patients with an ectopic pregnancy treated with a single dose of 50 mg/m(2) of methotrexate administered intramuscularly. The following predictive factors were evaluated: beta-hCG level on the day of hospital admission and the percent increment in beta-hCG in the 48-h interval prior to treatment. RESULTS: Treatment was successful in 49 cases (75.4%). In these cases, beta-hCG levels at hospitalization were lower when compared to the levels found in cases of therapeutic failure (1,928.9 vs. 4,828.6 mIU/ml, respectively; P<0.01), and the increment in beta-hCG level in the 48-h interval prior to treatment was smaller (13.1 vs. 36.3%, respectively; P=0.01). A beta-hCG measurement
机译:背景:为了评估甲氨蝶呤治疗异位妊娠治疗成功的前兆,在治疗前48小时内评估β-hCG水平(%)的增加。方法:在2002年4月至2006年11月之间,在圣保罗联邦大学进行了一项前瞻性观察性研究,研究对象是65例异位妊娠患者,单剂量50毫克/平方米(2)的甲氨蝶呤经肌肉注射治疗。评估了以下预测因素:入院当天的β-hCG水平和治疗前48小时间隔内β-hCG的增加百分比。结果:治疗成功49例,占75.4%。在这些情况下,与治疗失败的情况相比,住院时的β-hCG水平较低(分别为1,928.9 vs. 4,828.6 mIU / ml; P <0.01),而48例患者中β-hCG水平的升高治疗前的-h间隔较小(分别为13.1%和36.3%; P = 0.01)。住院当天的β-hCG测量值<或= 2,685 mIU / ml,治疗前48小时内β-hCG水平的增加<或= 11.1%,是治疗成功的因素,敏感性为79.6和61.7%,特异性分别为75%和81.3%。结论:入院当天的β-hCG测定值越低,治疗前48小时间隔内β-hCG的测定值越低,成功接受甲氨蝶呤治疗异位妊娠的可能性就越大。当住院当天的β-hCG测量值为<或= 2,685 mIU / ml,并且在治疗前48小时内其增加量为<或= 11.1%,使用甲氨蝶呤治疗的安全性较高。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号